Skip to main content

Table 2 Comparison of responder rate (FAS)

From: Zhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial

Responder rate

Treatment group (n = 177)

Control group (n = 180)

P value

4 W

38(21.47 %)

38(21.11 %)

0.108

8 W

61(34.46 %)

70(38.89 %)

0.455

12 W

106(59.89 %)

89(49.44 %)

0.002*

Follow-up period

97(54.80 %)

69(38.33 %)

<0.001*

  1. Note: Non-inferiority margin was −0.5
  2. *P < 0.05 for data comparison between groups after treatment
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us